via University of Manitoba
Researchers have developed a new antibiotic that can help in the fight against resistant bacteria, and they hope it will reach the patients.
Every day, people die from simple infections even though they have been treated with antibiotics. This is because more and more bacteria have become resistant to the types of antibiotics that doctors can prescribe.
It’s a huge societal problem and a crisis that we must solve. For example, by developing new antibiotics that can defeat the resistant bacteria, says professor of chemistry at the Department of Physics, Chemistry and Pharmacy, Poul Nielsen.
Resistant bacteria are not only known from pig farms, where it is becoming increasingly difficult to keep the pigsties disease-free. Hospitals are also experiencing with increasing regularity that, for example, infectious diseases cannot be controlled in patients. Thus, an infection in a surgical wound can become life-threatening even if the operation went well.
Resistance can occur very quickly
According to Poul Nielsen, it is important to be at the forefront of the development because the list of resistant bacteria will only grow, which means that the treatment options will be reduced. It is therefore important to develop alternatives that can be used when the current antibiotics no longer work.
Resistance can occur very quickly, and then it’s essential that we’re ready, he says.
Together with his research assistant Christoffer Heidtmann and Janne Kudsk Klitgaard from the Department of Biochemistry and Molecular Biology as well as Clinical Microbiology, he has developed a substance that has the potential to become a new effective antibiotic, and SDU has now taken out a patent for it.
Unlike traditional antibiotics such as penicillin, sulfonamides and tetracyclines, this antibiotic is from the pleuromutilin class.
The substance is developed in a medicinal chemistry project and recently published in the Journal of Medicinal Chemistry.
Out to doctors and patients – how?
The substance fights both resistant enterococcus, streptococcus and staphylococcus bacteria. The substance and the pleuromutilin class do this via a unique mechanism of action, which also causes resistance to develop at a very slow pace.
So far, the substance has been tested on bacteria and human cells. The next step towards becoming an approved drug is animal studies and then clinical studies in humans.
Maybe we should consider this a societal task, rather than a task that will only be solved if it’s financially attractive.
Poul Nielsen, professor
– If this substance is to reach doctors and patients as a drug, comprehensive and cost-intensive further development efforts are needed, which we can only initiate under the auspices of the university.
– The big pharmaceutical companies have that kind of money, but they are traditionally not interested in this kind of tasks, because they are not financially attractive, says Poul Nielsen.
Should it be a societal task?
According to Poul Nielsen, there are several reasons why it is not financially attractive to develop new antibiotics:
- Antibiotics are only taken for days or weeks. There is more money in drugs for chronically ill people, such as antidepressants or blood pressure medicine.
- Newly developed antibiotics will be backups and not used until the current antibiotics no longer work. So earnings are not just around the corner.
- The bacteria can also become resistant to a new antibiotic, and then it has to be taken off the market again.
– However, this doesn’t change the fact that the world community is in dire need of new effective drugs against antibiotic resistance. Maybe we should consider this a societal task, rather than a task that will only be solved if it’s financially attractive, says Poul Nielsen.
He and his colleagues hope that the work of further developing their new antibiotic can continue. Whether it will happen, and whether it will be in a public or private context, only time will tell.
Original Article: New weapon against resistant bacteria
More from: University of Southern Denmark
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- China to Regulate New and Emerging Pollutants Including Chemicals, Antibiotics
China will add 28 new and emerging environmental pollutants to its control list, which includes chemicals and antibiotics. The list of new and emerging pollutants subject to regulations mainly covers ...
- "One of the main reasons we won — we used no antibiotics for the past five years"
Michael and Alex McCarthy have been farming together for the past four years. Michael, a fifth-generation farmer, began helping his father out on the family farm almost 46 years ago. Since Alex’s ...
- Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading ...
- Maggots used to clean wounds in NHS as antibiotics fail some patients
Live maggots are being increasingly used to clean wounds by the NHS amid the threat of antibiotic resistance threatening patients' well-being. According to a report in The Daily Telegraph, the ...
- Animal Antibiotics Market Global Industry Trends,…
New report on the Global Animal Antibiotics Market for the period of 2021 to 2028 has been added by Fact.MR. And, the market’s growth dynamics have been identified and enumerated in it. Trends and ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, ...
- Antibiotic Resistance Market Sales Revenue to Significantly Increase in the Next Few Years
The Antibiotic Resistance Market is expected to be worth US 12 6 Bn at a CAGR of 4 between 2021 to 2031 Healthcare is going the digital way In other words artificial intelligence AI enabled medical ...
- Naturally Occurring Antibiotic Kills Lyme Disease and Nothing Else: A Potential Breakthrough Treatment
Antibiotic that selectively targets Lyme Disease, doesn't damage the microbiome, and doesn't spread resistance, was just found by scientists ...
- Preserving the lives of seniors and all Americans means preserving antibiotic use
Like COVID-19, antibiotic-resistant bacteria threatens us all, from “the greatest generation” to Generation Z.
- Antibiotic resistance takes toll on older Americans, study finds
Researchers are urging the federal government to do more to address the disproportionate health impact of drug-resistant bacteria on older Americans. Infections caused by pathogens resistant to ...
Go deeper with Google Headlines on: